FATE
Price
$1.17
Change
-$0.04 (-3.33%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
137.56M
68 days until earnings call
TCRX
Price
$1.37
Change
-$0.07 (-4.86%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
81.49M
82 days until earnings call
Interact to see
Advertisement

FATE vs TCRX

Header iconFATE vs TCRX Comparison
Open Charts FATE vs TCRXBanner chart's image
Fate Therapeutics
Price$1.17
Change-$0.04 (-3.33%)
Volume$11.22K
Capitalization137.56M
TScan Therapeutics
Price$1.37
Change-$0.07 (-4.86%)
Volume$23.02K
Capitalization81.49M
FATE vs TCRX Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. TCRX commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and TCRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (FATE: $1.20 vs. TCRX: $1.44)
Brand notoriety: FATE and TCRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 48% vs. TCRX: 174%
Market capitalization -- FATE: $137.56M vs. TCRX: $81.49M
FATE [@Biotechnology] is valued at $137.56M. TCRX’s [@Biotechnology] market capitalization is $81.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileTCRX’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • TCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both FATE and TCRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 6 TA indicator(s) are bullish while TCRX’s TA Score has 6 bullish TA indicator(s).

  • FATE’s TA Score: 6 bullish, 3 bearish.
  • TCRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than TCRX.

Price Growth

FATE (@Biotechnology) experienced а +18.81% price change this week, while TCRX (@Biotechnology) price change was +9.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

FATE is expected to report earnings on Jul 30, 2025.

TCRX is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($138M) has a higher market cap than TCRX($81.5M). FATE YTD gains are higher at: -27.273 vs. TCRX (-52.632). TCRX has higher annual earnings (EBITDA): -124.58M vs. FATE (-176.58M). FATE has more cash in the bank: 279M vs. TCRX (252M). FATE has less debt than TCRX: FATE (85.3M) vs TCRX (97M). FATE has higher revenues than TCRX: FATE (13.6M) vs TCRX (4.42M).
FATETCRXFATE / TCRX
Capitalization138M81.5M169%
EBITDA-176.58M-124.58M142%
Gain YTD-27.273-52.63252%
P/E RatioN/AN/A-
Revenue13.6M4.42M308%
Total Cash279M252M111%
Total Debt85.3M97M88%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATETCRX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NINE0.530.03
+5.45%
Nine Energy Service
CRZBY30.170.48
+1.63%
Commerzbank AG
IVR7.36N/A
N/A
Invesco Mortgage Capital
DBOEY32.38-0.11
-0.34%
Deutsche Boerse AG
GNGBY19.54-0.37
-1.87%
Getinge AB

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+2.56%
ALLO - FATE
57%
Loosely correlated
N/A
NTLA - FATE
56%
Loosely correlated
+2.83%
CRSP - FATE
54%
Loosely correlated
+1.46%
CCCC - FATE
53%
Loosely correlated
N/A
CRBU - FATE
52%
Loosely correlated
+7.88%
More

TCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TCRX has been loosely correlated with IMNM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRX jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCRX
1D Price
Change %
TCRX100%
+9.09%
IMNM - TCRX
46%
Loosely correlated
+6.82%
FATE - TCRX
45%
Loosely correlated
+2.56%
IDYA - TCRX
43%
Loosely correlated
N/A
SYRE - TCRX
43%
Loosely correlated
+1.96%
STRO - TCRX
42%
Loosely correlated
+7.67%
More